Farmas USA

Pues un poco de todo, indicadores,si hay alguna new cercana etc... y sobretodo leer mucho de lo que hay por internet XD

Valores:

ZIOP,FREE,NWBO,VNDA,DRYS,THLD,BAXS,NQ,ACHN

Yo vendí el otro día a 6,21 con estupendas pluses. También me parecía que estaba perdiendo fuerza. Pero vamos, que estoy feliz como una perdiz.
MACK

Zoka ver https://www.tradingview.com/x/ZGYgwBjC/

Mack

Enhorabuena porque creo que tu la llevabas desde bien abajo, así que felices profits. Mi razón para no venderla fue la conferencia de la semana que viene. Es un poco cara o cruz porque si liberan datos pueden ser positivos o negativos. Como la llevo con margen me puedo permitir quedarme

Muchas gracias!Si, le saqué un 80% nada menos. MACK
Pero vamos, que todavía no me resuelve el roto de AMRN, je je
Ahora estoy un poco desconcertado, porque veo que se están mencionando unas cuantas, y no soy capaz de decirme por ninguna...

La jolla Pharmaceuticals

voy a seguir el chicharraco y ya os iré comentando, o se le fué la pinza al tipo, la verdad es un ganador, ya veremos por donde sale. la trayectoria es buena.

Management
George F. Tidmarsh, M.D., Ph.D.

President, Chief Executive Officer and Secretary

Dr. Tidmarsh’s 22 years of experience in biotechnology include the successful clinical development of three FDA-approved drugs. Up until his appointment to La Jolla, Dr. Tidmarsh served as the Chief Executive Officer of Solana Therapeutics, Inc. Previously, he served as the Chief Executive Officer of Horizon Pharma, Inc. (NASDAQ: HZNP), a company he founded in 2005. While at Horizon, he led all aspects of development of Duexis, which was approved by the FDA for the treatment of conditions such as osteoarthritis and rheumatoid arthritis. He also founded Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) and held senior positions at Coulter Pharmaceutical, Inc. [acquired by GlaxoSmithKline (NYSE: GSK)] and SEQUUS Pharmaceuticals, Inc. [acquired by Johnson & Johnson (NYSE: JNJ)]. While at Coulter and SEQUUS, Dr. Tidmarsh led the clinical development of BEXXAR and Doxil, respectively, two FDA-approved anti-cancer agents. Dr. Tidmarsh received his M.D. and Ph.D. from Stanford University, where he also completed fellowship training in Pediatric Oncology and Neonatology and remains a Consulting Professor of Pediatrics and Neonatology.

N DIEGO, CA, Dec 16, 2013 (Marketwired via COMTEX) -- La Jolla Pharmaceutical Company LJPC +1.00% (the "Company" or "La Jolla"), a leader in the development of therapeutics targeting significant unmet life-threatening diseases, today announced that it has completed enrollment of its placebo-controlled, randomized Phase 2 clinical trial of GCS-100 in patients with chronic kidney disease ("CKD"). A total of 121 patients with Stage 3b or 4 CKD were enrolled in the study. The Company expects to announce data on the primary endpoint in April 2014 and the full data package before the end of the second quarter 2014.

"We would like to gratefully thank the patients and Investigators for their participation in our Phase 2 study, and we look forward to analyzing the data," said George F. Tidmarsh, M.D., Ph.D., President and CEO of La Jolla. "We plan to make all data available to the public as soon as possible."

This Phase 2 study was designed to enroll approximately 117 subjects, at least 18 years of age, with Stage 3b or 4 CKD. Subjects were randomly assigned 1:1:1 to treatment with placebo, 1.5 or 30 mg/m2 of GCS-100. In addition, randomization was stratified by baseline renal function, defined by eGFR values of 15-29 and 30-44 mL/min/1.73m2. Once randomized, subjects receive eight consecutive weekly doses of their assigned treatment with a follow-up four weeks after treatment.

The primary objective of this study is to compare the change in eGFR from baseline to the end of treatment between placebo and GCS-100 treatment. The secondary objective is to determine the safety and tolerability of GCS-100 administered for 8 weeks relative to placebo. In addition, the study measures the effect of GCS-100 on circulating galectin-3 and other markers of disease activity.

About La Jolla Pharmaceutical Company La Jolla Pharmaceutical Company is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics for chronic organ failure and cancer. GCS-100, the Company's lead product candidate, is a first-in-class inhibitor of galectin-3, a novel molecular target implicated in chronic organ failure and cancer. LJPC-501, the Company's second product candidate, is a natural peptide for the treatment of hepatorenal syndrome. For more information on the Company please visit http://www.ljpc.com .

dilución y buitres que han entrado. entre ellos los maravillosos Baker Brothers. http://www.youtube.com/watch?v=EHV0zs0kVGg

Comprador

No. acciones de
Capital Accionario N º de acciones de la Serie
F Acciones preferentes Precio de compra total

Tang Capital Partners, LP

17979016 175.780 $ 1,434,311.12

Kevin C. Tang Fundación, Inc.

823413 8.050 $ 65,688.900
Boxer Capital, LLC

17650677 114.453 $ 1,350,000.39

MVA Investors, LLC

1961186 12.717 $ 150,000.02

RTW Investments, LLC

19420842 140.541 $ 1,499,999.94

Baker Brothers Life Sciences, LP

14882585 2,425.722 $ 3,467,502.95

14159, LP

372856 60.772 $ 86,871.92

667, LP (Cuenta # 1)

1134381 184.894 $ 264,300.67

667, LP (Cuenta # 2)

778247 126.847 $ 181,324.29

David S Caza

9500000 - $ 665,000.00


Colt Ventures, Ltd.

5714286 - $ 400,000.02

DAFNA Lifescience, Ltd.

1142500 - $ 79,975.00

DAFNA Lifescience, Market Neutral Ltd.

250000 - $ 17,500.00


DAFNA Lifescience, Select Ltd.

2179000 - $ 152,530.00


George F. Tidmarsh, MD Ph.D.

1071429 - $ 75,000.03


MTS Health Partners, LP

857071 - $ 59,994.97

Jeffrey Benison IRA

714286 - $ 50,000.02

Total

96431775 3,249.776 $ 10,000,000.25

http://www.sec.gov/Archives/edgar/data/920465/000119312513377211/d603170dex101.htm aquí esta más claro que el copia pega no quedo bien.

Comentaba ayer que Fidelity se habia hecho con el 9% de ARIA.
No es asi. Es propietaria del 9% tras haber vendido 10 millones de acciones, antes poseia 27 millones (14,5%)

Esto ha sucedido, doy por hecho, durante la debacle del gap down.

Veremos si tiene repercusion el Lunes. No creo.

ARIA

ARIA
Esto cambia la cosa. Los volúmenes han bajado y está un tanto incierta. En estas condiciones me daría duda entrar y más cuando parece que ya llegó cerca de su precio objetivo 7,12 en yahoo.
Suerte para los valientes
S2

http://www.americanbulls.com/SignalPage.aspx?lang=en&Ticker=ARIA